Brainomix and Endeavor BioMedicines presented positive results from quantitative image analysis of Phase 2a #IPF Trial at ERS2026 using AI-powered quantitative CT analysis with e-Lung in the ENV-IPF-101 Phase 2a trial of taladegib.

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung diseases. Our flagship product, Brainomix 360 Stroke, is the world's first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung automatically identifies and quantifies features on CT lung scans enabling clinicians to more easily identify changes including subtle deteriorations over multiple scan timepoints. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries.